The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation
1 other identifier
observational
10
1 country
1
Brief Summary
Iron metabolism may undergo changes during exercise, with reductions in classical iron status markers due to a variety of postulated mechanism which include hemodilution, increased iron loss, hemolysis and increased iron storage in muscles. Furthermore, it has been reported that vigorous training increases hepcidin, a central regulatory peptide in iron metabolism. This increase has been ascribed to the presence of subclinical inflammation. Increased hepcidin levels may reduce iron bioavailability and iron incorporation in erythrocytes. Twenty healthy men subjects will be recruited as subjects for this study. Subjects should be generally healthy, with no history of blood donation in the last 6 months, should weigh less than 85 Kg, and not take iron supplements and/or multivitamin supplements. Subjects should have familiarity to sports and running, but not currently (i.e. in the past 3 months) training for more than 1h per week on average. The aim of this study is to measure an iron bioavailability during a resting and an exercise phase lasting approx. 14 days with training sessions on alternate days. Subjects will participate in both restign and exercising protocols and act as their own controls during the study. Iron bioavailability will be measured via the incorporation of stable isotopic labels 14 days after administration. To control for changes in blood volume during the course of the study, blood volume of the participating subjects will be measured before and after the exercise phase with the CO-rebreathing method. Measurement of iron bioavailability and iron incorporation in a resting and exercising phase will allow determine if the increased level of hepcidin seen in in exercise will induce a lower iron bioavailability and iron incorporation during exercise.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
November 7, 2012
CompletedFirst Posted
Study publicly available on registry
November 21, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2013
CompletedSeptember 13, 2013
September 1, 2013
2 months
November 7, 2012
September 12, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Iron bioavailability from Stable isotopic labels
Up to 2 months
Secondary Outcomes (1)
Blood volume increase during exercise
Up to 2 months
Other Outcomes (1)
Hepcidin levels and inflammation markers (C-Reactive Protein, 1-Alpha acid glycoprotein)
Up to 2 months
Study Arms (1)
Difference in Iron bioavailabilty exercise and resting phase
the subjects will act as their own control during the study
Interventions
the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
Eligibility Criteria
Subjects studying or working at the University of Zürich or ETH Zürich
You may qualify if:
- men, Generally Healthy age between 18-50 years;
- BMI between 18-25;
- nonanemic (Hb \< 120 g/L);
- no intake of vitamins and nutritional supplements;
- no recent blood donation (\<4 months);
- no previous participation in studies with stable iron isotopes in the past.
You may not qualify if:
- Chronic diseases, Metabolic diseases, GI tract diseases (self reported)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ETH Zürich
Zurich, 8092, Switzerland
Related Publications (2)
Cercamondi CI, Egli IM, Ahouandjinou E, Dossa R, Zeder C, Salami L, Tjalsma H, Wiegerinck E, Tanno T, Hurrell RF, Hounhouigan J, Zimmermann MB. Afebrile Plasmodium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women. Am J Clin Nutr. 2010 Dec;92(6):1385-92. doi: 10.3945/ajcn.2010.30051. Epub 2010 Oct 6.
PMID: 20926522BACKGROUNDMoretti D, Mettler S, Zeder C, Lundby C, Geurts-Moetspot A, Monnard A, Swinkels DW, Brittenham GM, Zimmermann MB. An intensified training schedule in recreational male runners is associated with increases in erythropoiesis and inflammation and a net reduction in plasma hepcidin. Am J Clin Nutr. 2018 Dec 1;108(6):1324-1333. doi: 10.1093/ajcn/nqy247.
PMID: 30351387DERIVED
Biospecimen
Whole blood and serum samples
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Diego Moretti, PhD
ETH Zürich
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, MD
Study Record Dates
First Submitted
November 7, 2012
First Posted
November 21, 2012
Study Start
October 1, 2012
Primary Completion
December 1, 2012
Study Completion
June 1, 2013
Last Updated
September 13, 2013
Record last verified: 2013-09